

Adi F. Gazdar, MD SCIENTIFIC SYMPOSIUM & REMEMBRANCE



A celebration of life and science

Tuesday February 12, 2019
NG3.112 — T. Boone Pickens Auditorium
University of Texas Southwestern Medical Center

UTSouthwestern
Harold C. Simmons
Comprehensive Cancer Center

Live Stream: streaming.utsouthwestern.edu/gazdar.html

SYMPOSIUM PROGRAM

9:00

John D. Minna, MD
UT Southwestern
Ignacio Wistuba, MD
MD Anderson Cancer Center
Symposium Introduction

9:10

David P. Carbone, MD, PhD
Ohio State University
Co-Expression Analysis Reveals Mechanisms Underlying the Varied Roles of NOTCH1 in NSCLC

9:30

Paul A. Bunn Jr., MD
University of Colorado Cancer Center
Remembering AFG's Role in Retrovirus Research

9:40

David McFadden, MD, PhD
UT Southwestern
Molecular Analyses of Genetically Engineered Mouse Models of SCLC

10:00

Fred Hirsch, MD, PhD
Tisch Cancer Institute, Icahn School of Medicine
Remembering AFG and the IASLC

10:10

Natasha Rekhtman, MD, PhD
Memorial Sloan Kettering Cancer Center
Pathology Studies of Neuroendocrine Lung Cancer

10:30 BREAK

10:40

James L. Mulshine, MD
Rush University
Remembering AFG and the NCI-Navy Branch

10:50

Humam Kadara, PhD
MD Anderson Cancer Center
Molecular Analyses of Lung Cancer Premalignancy

11:10

Peter Ujjhazy, MD, PhD
National Cancer Institute
Remembering AFG and the Lung Cancer SPORE Program

11:20

Steven Dubinett, MD
University of California Los Angeles
Immune Contexture of Lung Adenocarcinoma Premalignancy

11:40

Sudhir Srivastava, PhD, MPH
National Cancer Institute
Remembering Adi Gazdar and His Contributions to My Journey in Biomarker Research

11:50

Fang Huang, MD, PhD
UT Southwestern
Inosine Monophosphate Dehydrogenase Dependence in a Subset of SCLC

12:10 LUNCH

12:55

John T. Poirier, PhD
Memorial Sloan Kettering Cancer Center
Biological Classification of Small Cell Lung Cancers: An Integration of Human and Mouse Model Data

1:15

Jack A. Roth, MD
MD Anderson Cancer Center
Immunogene Therapy for Lung Cancer

1:35

Wilbur Franklin, MD
University of Colorado
Pathologists Working with AFG

1:45

David Shames, PhD
Genentech
Development and Application of Lung Cancer Biomarkers

2:05

Ming Tsao, MD, FRCPC
Princess Margaret
Investigating Mechanisms of Drug Persistence Using Lung Adenocarcinoma PDX Model

2:25

Michele Carbone, MD, PhD
University of Hawaii
Remembering AFG and Mesothelioma Research

2:45

Karine Pozo, PhD
UT Southwestern
Role of Transcription Factor Lineage Oncogenes in SCLC Pathogenesis

3:05

John D. Minna, MD
UT Southwestern,
Ignacio Wistuba, MD and
Carmen Behrens, MD
MD Anderson Cancer Center
Remembering AFG as a Friend, Mentor, Colleague, and Teacher

3:15 ADJOURN

Adi F. Gazdar, MD SCIENTIFIC SYMPOSIUM & REMEMBRANCE


Adi F. Gazdar, MD was a groundbreaking scientist and pathologist, loyal friend, and inspiring mentor.

Dr. Gazdar was born in Bombay, India and earned a medical degree from Guy's Hospital Medical School at the University of London. He completed pathology residencies at Peter Bent Brigham Hospital and New England Deaconess Hospital in Boston before joining the National Cancer Institute (NCI) in 1968.

During his remarkable five-decade career, Dr. Gazdar served 23 years with the NCI as a senior scientist and section head. He led the Viral Pathology Section initially; then, the Human Tumor Cell Biology Laboratory for the NCI's VA Medical Oncology Branch from 1975 to 1981; and the Human Tumor Cell Biology Section for the NCI-Navy Oncology Branch from 1981 to 1991.

In 1991, he joined long-time colleague John D. Minna, MD at the University of Texas Southwestern Medical Center in Dallas, where he had a distinguished 27-year career as Professor of Pathology, the W. Ray Wallace Distinguished Chair in Molecular Oncology Research, and Deputy Director of the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research.

Dr. Gazdar's laboratory efforts yielded the first large panel lung and breast cancer cell lines—used by investigators around the world. He also developed molecular methods for detecting early lung tumors and identified several genes involved in the pathogenesis of different cancers. In lung cancer, he uncovered mutated genes dysregulated by mutation and DNA methylation, provided some of the first work characterizing neuroendocrine cancers such as small cell lung cancer, and played a major role in the discovery of the mutated epidermal



growth factor receptor (EGFR) gene as a therapeutic target in lung cancer arising in never-smokers.

Dr. Gazdar published more than 800 articles, book chapters, and commentaries. He has been cited over 110,000 times, ranking him in the top 1% of scientists in the biomedical field.

His numerous honors and recognitions include the prestigious Jacqueline Seroussi Memorial Foundation for Cancer Research in Israel in 2004 and the Mary J. Matthews Pathology/Translational Research award from the International Association for the Study of Lung Cancer (IASLC) in 2003.

Dr. Gazdar was an inspiring role model for many young scientists, mentoring over 100 post-doctoral fellows from around the world. In 2017, IASLC established the Adi Gazdar Translational Research Fellowship Award to honor his legacy in lung cancer training.



Celia Gazdar and Dr. Adi F. Gazdar 2017